Cadila Healthcare informs about press release

10 Dec 2021 Evaluate

Cadila Healthcare has informed that it enclosed a copy of press release dated December 10, 2021 titled ‘Zydus announces EPICS-IIITM Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC’.

The above information is a part of company’s filings submitted to BSE

Zydus Lifesciences Share Price

896.60 3.15 (0.35%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×